TISIDB

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted
Domain	PF08702 Fibrinogen alpha/beta chain family PF00147 Fibrinogen beta and gamma chains
Function	Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways.

> Gene Ontology [ TOP ]
Biological Process	GO:0002250 adaptive immune response GO:0002576 platelet degranulation GO:0002790 peptide secretion GO:0002791 regulation of peptide secretion GO:0002793 positive regulation of peptide secretion GO:0003013 circulatory system process GO:0003018 vascular process in circulatory system GO:0006887 exocytosis GO:0006959 humoral immune response GO:0007160 cell-matrix adhesion GO:0007596 blood coagulation GO:0007599 hemostasis GO:0008015 blood circulation GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors GO:0009306 protein secretion GO:0009914 hormone transport GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0010720 positive regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010770 positive regulation of cell morphogenesis involved in differentiation GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0010817 regulation of hormone levels GO:0015833 peptide transport GO:0016485 protein processing GO:0017157 regulation of exocytosis GO:0019229 regulation of vasoconstriction GO:0019730 antimicrobial humoral response GO:0019731 antibacterial humoral response GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0022604 regulation of cell morphogenesis GO:0023061 signal release GO:0030072 peptide hormone secretion GO:0030168 platelet activation GO:0030193 regulation of blood coagulation GO:0030195 negative regulation of blood coagulation GO:0030198 extracellular matrix organization GO:0031589 cell-substrate adhesion GO:0031638 zymogen activation GO:0031639 plasminogen activation GO:0032102 negative regulation of response to external stimulus GO:0034109 homotypic cell-cell adhesion GO:0034113 heterotypic cell-cell adhesion GO:0034114 regulation of heterotypic cell-cell adhesion GO:0034116 positive regulation of heterotypic cell-cell adhesion GO:0034446 substrate adhesion-dependent cell spreading GO:0035150 regulation of tube size GO:0042310 vasoconstriction GO:0042730 fibrinolysis GO:0042742 defense response to bacterium GO:0042886 amide transport GO:0043062 extracellular structure organization GO:0043152 induction of bacterial agglutination GO:0043410 positive regulation of MAPK cascade GO:0044057 regulation of system process GO:0044320 cellular response to leptin stimulus GO:0044321 response to leptin GO:0045055 regulated exocytosis GO:0045785 positive regulation of cell adhesion GO:0045907 positive regulation of vasoconstriction GO:0045921 positive regulation of exocytosis GO:0046879 hormone secretion GO:0046883 regulation of hormone secretion GO:0046887 positive regulation of hormone secretion GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0050817 coagulation GO:0050818 regulation of coagulation GO:0050819 negative regulation of coagulation GO:0050878 regulation of body fluid levels GO:0050880 regulation of blood vessel size GO:0051047 positive regulation of secretion GO:0051222 positive regulation of protein transport GO:0051258 protein polymerization GO:0051592 response to calcium ion GO:0051604 protein maturation GO:0060627 regulation of vesicle-mediated transport GO:0061041 regulation of wound healing GO:0061045 negative regulation of wound healing GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070374 positive regulation of ERK1 and ERK2 cascade GO:0070527 platelet aggregation GO:0070555 response to interleukin-1 GO:0071347 cellular response to interleukin-1 GO:0072376 protein activation cascade GO:0072378 blood coagulation, fibrin clot formation GO:0072577 endothelial cell apoptotic process GO:0090066 regulation of anatomical structure size GO:0090087 regulation of peptide transport GO:0090276 regulation of peptide hormone secretion GO:0090277 positive regulation of peptide hormone secretion GO:0097191 extrinsic apoptotic signaling pathway GO:0098542 defense response to other organism GO:1900024 regulation of substrate adhesion-dependent cell spreading GO:1900026 positive regulation of substrate adhesion-dependent cell spreading GO:1900046 regulation of hemostasis GO:1900047 negative regulation of hemostasis GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1903034 regulation of response to wounding GO:1903035 negative regulation of response to wounding GO:1903522 regulation of blood circulation GO:1903524 positive regulation of blood circulation GO:1903532 positive regulation of secretion by cell GO:1904019 epithelial cell apoptotic process GO:1904035 regulation of epithelial cell apoptotic process GO:1904036 negative regulation of epithelial cell apoptotic process GO:1904951 positive regulation of establishment of protein localization GO:2000351 regulation of endothelial cell apoptotic process GO:2000352 negative regulation of endothelial cell apoptotic process GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function	GO:0030674 protein binding, bridging GO:0050839 cell adhesion molecule binding GO:0051087 chaperone binding GO:0060090 binding, bridging
Cellular Component	GO:0005577 fibrinogen complex GO:0005938 cell cortex GO:0009897 external side of plasma membrane GO:0030141 secretory granule GO:0031091 platelet alpha granule GO:0031093 platelet alpha granule lumen GO:0031983 vesicle lumen GO:0034774 secretory granule lumen GO:0060205 cytoplasmic membrane-bounded vesicle lumen GO:0072562 blood microparticle GO:0098552 side of membrane GO:0099503 secretory vesicle GO:0099568 cytoplasmic region

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04610 Complement and coagulation cascades hsa04611 Platelet activation
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-422475: Axon guidance R-HSA-140875: Common Pathway of Fibrin Clot Formation R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1474244: Extracellular matrix organization R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-140877: Formation of Fibrin Clot (Clotting Cascade) R-HSA-170968: Frs2-mediated activation R-HSA-179812: GRB2 events in EGFR signaling R-HSA-354194: GRB2 R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-354192: Integrin alphaIIb beta3 signaling R-HSA-216083: Integrin cell surface interactions R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-5674135: MAP2K and MAPK activation R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-6802957: Oncogenic MAPK signaling R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF R-HSA-76009: Platelet Aggregation (Plug Formation) R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-114608: Platelet degranulation R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-5686938: Regulation of TLR by endogenous ligand R-HSA-76005: Response to elevated platelet cytosolic Ca2+ R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-6802952: Signaling by BRAF and RAF fusions R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-6802949: Signaling by RAS mutants R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-6802948: Signaling by high-kinase activity BRAF mutants R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-168898: Toll-Like Receptors Cascades R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation R-HSA-372708: p130Cas linkage to MAPK signaling for integrins

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04610 Complement and coagulation cascades
hsa04611 Platelet activation

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-140875: Common Pathway of Fibrin Clot Formation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1474244: Extracellular matrix organization
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-140877: Formation of Fibrin Clot (Clotting Cascade)
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-354194: GRB2
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-354192: Integrin alphaIIb beta3 signaling
R-HSA-216083: Integrin cell surface interactions
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5674135: MAP2K and MAPK activation
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-6802957: Oncogenic MAPK signaling
R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-76009: Platelet Aggregation (Plug Formation)
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-5686938: Regulation of TLR by endogenous ligand
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-6802952: Signaling by BRAF and RAF fusions
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-6802949: Signaling by RAS mutants
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-6802948: Signaling by high-kinase activity BRAF mutants
R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-372708: p130Cas linkage to MAPK signaling for integrins

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FGB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FGB in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FGB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	1.359	0.182
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.032	0.984
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	2.405	0.0746
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.131	0.89
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.294	0.825
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.061	0.968
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.876	0.499
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.841	0.669
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.593	0.76
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.802	0.758
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.046	0.99
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-1.493	0.00756

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FGB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	0	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FGB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FGB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FGB. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FGB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FGB expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FGB and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FGB
Name	fibrinogen beta chain
Aliases	fibrinogen, B beta polypeptide; HEL-S-78p; epididymis secretory sperm binding protein Li 78p
Chromosomal Location	4q28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FGB collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting FGB.

ID	Name	Drug Type	Targets	#Targets
DB00364	Sucralfate	Small Molecule	EGF, FGA, FGB, FGF2, FGG	5
DB04919	Alfimeprase	Biotech	FGA, FGB	2
DB11311	Prothrombin	Biotech	CPB2, F13A1, FGA, FGB	4
DB13151	Anti-inhibitor coagulant complex	Biotech	F10, F13A1, F2, F5, F7, F8, FGA, FGB	8

Browse FGB